R&D | March 28, 2026
AbbVie stakes claim to redefine skin disease treatment at Global Dermatology Summit
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
This marks the second indication for which gumokimab has gained NDA review acceptance
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients
Through the new DTP platform, Novartis will make Cosentyx available to patients at a price that reflects the average savings typically retained by insurers and pharmacy benefit managers
Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
